Last updated on November 2017

Outcomes Study to Assess Statin Residual Risk Reduction With Epanova in High CV Risk Patients With Hypertriglyceridemia (STRENGTH)


Brief description of study

Outcomes Study to Assess Statin Residual Risk Reduction With Epanova in High CV Risk Patients With Hypertriglyceridemia (STRENGTH)

Detailed Study Description

The study is a randomized, double-blind, well-controlled (corn oil), parallel group design that will enroll approximately 13,000 patients with hypertriglyceridemia and high risk for CVD to be randomized 1:1 to either corn oil + statin or Epanova + statin, once daily, for approximately 3-5 years as determined when the number of MACE outcomes is reached.

Clinical Study Identifier: TX6273

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Misha Lewis

Community Clinical Research Center
Muncie, IN USA
  Connect »